Physician profile
Robert D Schumaker
NPI 1679573752
$21,489.16
in general payments reported to CMS, 2019-2025
79 companies · $3,101 in 2025
The $3,101 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,909 · 2020: $2,194 · 2021: $4,223 · 2022: $3,224 · 2023: $3,442 · 2024: $3,396 · 2025: $3,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,774 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,774.43 |
| Education | $164.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,461.13 | 2019-2025 | |
| Epizyme, INC. | $1,383.57 | 2021 | |
| Merck Sharp & Dohme LLC | $1,247.53 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $1,246.37 | 2019-2025 | Enhertu, Tagrisso, Calquence |
| Amgen INC. | $1,194.03 | 2019-2023 | Kyprolis, Vectibix, Xgeva |
| E.R. Squibb & Sons, L.L.C. | $1,152.89 | 2019-2025 | Opdivo, Opdualag, Pomalyst |
| Pfizer INC. | $1,010.33 | 2019-2025 | |
| Janssen Biotech, INC. | $915.85 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Daiichi Sankyo INC. | $736.77 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Incyte Corporation | $724.24 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Celgene Corporation | $669.17 | 2019-2025 | Reblozyl, Pomalyst |
| Seagen INC. | $649.95 | 2019-2025 | Tukysa, Adcetris, Padcev |
| Genentech USA, INC. | $618.90 | 2019-2025 | Phesgo, Perjeta, Itovebi |
| Genzyme Corporation | $574.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $498.60 | 2020-2025 | Ojjaara, Jemperli, Zejula |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $467.95 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Exelixis INC. | $427.33 | 2019-2025 | Cabometyx |
| Eisai INC. | $419.35 | 2019-2025 | |
| Abbvie INC. | $395.94 | 2020-2025 | Venclexta, Epkinly |
| Regeneron Healthcare Solutions, INC. | $356.12 | 2019-2025 | Libtayo |
| Puma Biotechnology, INC. | $353.27 | 2020-2025 | |
| Astellas Pharma US INC | $329.91 | 2019-2025 | Vyloy, Padcev, Xtandi |
| Gilead Sciences, INC. | $314.84 | 2019-2025 | Trodelvy |
| Mirati Therapeutics, INC. | $309.46 | 2023-2024 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $289.38 | 2019-2025 | |
| Mckesson Drug Company LLC | $253.29 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $250.84 | 2020-2023 | Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $213.04 | 2019-2025 | Ninlaro, Alunbrig |
| Array Biopharma INC | $198.82 | 2019-2025 | Xalkori, Mektovi, Lorbrena |
| Emd Serono, INC. | $194.76 | 2020-2025 | Bavencio |
| Rigel Pharmaceuticals, INC. | $164.61 | 2019-2025 | Gavreto, Tavalisse, Rezlidhia |
| Beigene USA, INC. | $161.48 | 2022-2024 | Brukinsa, Tevimbra |
| Myriad Genetic Laboratories, INC. | $158.61 | 2021-2025 | Myrisk, Precisetumor |
| Taiho Oncology, INC. | $151.58 | 2019-2025 | |
| Kite Pharma, INC. | $137.33 | 2020-2025 | Yescarta |
| Aveo Pharmaceuticals, INC. | $135.48 | 2021-2025 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $134.47 | 2020-2025 | Onivyde |
| Alexion Pharmaceuticals, INC. | $134.47 | 2020-2025 | Ultomiris |
| Karyopharm Therapeutics INC. | $123.40 | 2020-2022 | |
| Blueprint Medicines Corporation | $80.93 | 2023-2025 | Ayvakit |
| Jazz Pharmaceuticals INC. | $77.08 | 2020-2025 | |
| Novocure INC. | $74.83 | 2024-2025 | Optune Lua (Novottf-200t) |
| Pharmaessentia USA Corporation | $65.27 | 2023-2025 | Besremi |
| Springworks Therapeutics, INC. | $62.38 | 2024-2025 | Ogsiveo |
| Heron Therapeutics, INC. | $62.22 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $59.96 | 2021-2025 | Monoferric |
| Biocompatibles, INC. | $59.58 | 2019 | |
| Tersera Therapeutics LLC | $57.61 | 2021-2022 | |
| Acceleron Pharma, INC. | $52.29 | 2020-2021 | |
| Morphosys, US INC. | $43.35 | 2021-2023 | Monjuvi |
| Adc Therapeutics America, INC. | $43.03 | 2023-2024 | |
| Agios Pharmaceuticals, INC. | $40.97 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $37.92 | 2019 | |
| Kyowa Kirin, INC. | $37.66 | 2024 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.26 | 2020-2024 | Gilotrif |
| Stemline Therapeutics INC. | $34.71 | 2023 | Orserdu |
| Clovis Oncology, INC. | $31.26 | 2021 | |
| Secura Bio, INC. | $29.30 | 2020-2022 | |
| Macrogenics, INC. | $26.04 | 2021 | |
| Caris Mpi, INC. | $25.73 | 2025 | Mi Cancer Seek |
| Deciphera Pharmaceuticals INC. | $24.93 | 2021 | |
| Amag Pharmaceuticals, INC. | $24.10 | 2021 | |
| Coherus Oncology, INC. | $23.91 | 2022 | |
| Servier Pharmaceuticals LLC | $22.82 | 2025 | |
| Beone Medicines USA, INC. | $22.35 | 2025 | Brukinsa |
| Genmab U.S., INC. | $22.22 | 2024 | Epkinly |
| Janssen Pharmaceuticals, INC | $22.00 | 2024 | Rybrevant |
| Tg Therapeutics, INC. | $20.87 | 2021 | |
| Iovance Biotherapeutics, INC. | $20.85 | 2025 | Amtagvi |
| Geron Corporation | $16.76 | 2025 | Rytelo |
| Apellis Pharmaceuticals, INC. | $16.52 | 2023 | Empaveli |
| Sobi, INC | $15.10 | 2022 | |
| Verastem, INC. | $14.85 | 2020 | |
| Dova Pharmaceuticals | $12.06 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $11.43 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,784.80 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schumaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.